Skip to main content
. 2018 Mar 8;8(8):2189–2201. doi: 10.7150/thno.22800

Figure 3.

Figure 3

(A) Treatment with Dex-P caused significant tumor growth inhibition (upper panel) and prolonged survivals (lower). (B) Dose-response inhibitory activities for combination treatment of Kasumi-1 cells with Dex and Cytarabine (upper), together with calculated combination indices (CI) of 0.13-0.75 showing strong synergy (lower).